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  1 
Summary 
 
The production and certification of ERM-DA470k/IFCC, a new serum protein reference 
material intended to replace ERM-DA470, is described.  
Serum was produced from blood collected in 6 blood collection centres according to a 
procedure ensuring that it was obtained from healthy donors, and that the lipid content of the 
serum was low.  
The serum was processed in 5 batches, and then pooled, spiked with B2M and CRP and 
filled into vials (1 mL serum per vial). The serum was lyophilised in the vials, afterwards 
closed with rubber stoppers and screw caps and stored at -70 °C. The stability and 
homogeneity of the material were assessed for 14 proteins, including CER and B2M. 
ERM-DA470k/IFCC was characterised for 12 proteins using the reference material ERM-
DA470 as calibrant. This was achieved using a value transfer protocol that can be 
considered as reference procedure.  
The techniques used to measure the protein concentrations were immunonephelometry, 
immunoturbidimetry, and for ALB also visible spectrometry. The measurements were 
performed with different platform/reagent combinations (Abbott Architect, Beckman Immage, 
BN II and BN ProSpec, different Hitachi instruments, Roche Integra, LX 2200, and Olympus 
AU640). In total 18 laboratories participated in the value assignment, 4 using open value 
transfer procedures, 12 using closed value transfer procedures, and 2 using both open and 
closed procedures. 
The results show that open and closed value transfer procedures give very similar results, 
and lead to robust values for A2M, AAG, AAT, ALB, C3c, C4, HPT, IgA, IgG, IgM, TRF, and 
TTR.  
 
 
Disclaimer:  
Certain commercial equipment, instruments, and materials are identified in this paper to specify 
adequately the experimental procedure. In no case does such identification imply recommendation or 
endorsement by the European Commission, nor does it imply that the material or equipment is 
necessarily the best available for the purpose. 
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GLOSSARY 
AAG  α1 acid glycoprotein (orosomucoid) 
AAT  α1 antitrypsin (α1-protease inhibitor) 
A2M  α2 macroglobulin 
ACT  α1 antichymotrypsin 
ALB  albumin 
ANOVA  analysis of variance 
b  slope in the equation of linear regression y = a + bx 
Bit  unit of the analog-to-digital converter of the light detector 
c  mass concentration c = m / V (mass / volume), the unit is g/L 
B2M  β2 microglobulin 
C3c  complement 3c 
C3  complement 3 
C4  complement 4 
CASO  Casein Soy  
CER  ceruloplasmin 
CRM  Certified Reference Material 
CRP  C-reactive protein 
ERM  European Reference Material 
HBV  hepatitis B virus 
HBsAg  hepatitis B surface antigen 
HCV  hepatitis C virus 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV  human immunodeficiency virus 
HPT  haptoglobin 
IFCC  International Federation of Clinical Chemistry and Laboratory Medicine 
IgA  immunoglobulin A 
IgG  immunoglobulin G 
IgM  immunoglobulin M 
IRMM  Institute for Reference Materials and Measurements 
IU  International Units 
IVD  In Vitro Diagnostics 
k  coverage factor 
KIU  Kallikrein Inhibitor Unit 
m  mass 
MSbb  mean sum of squares between bottles 
MSwb  mean sum of squares within bottles 
N  number of samples analysed 
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n  number of subsamples analysed 
NC  not calculable 
ND  not detectable 
PAGE  polyacrylamide gel electrophoresis 
RM  reference material 
RF  Rheumatoid Factor 
R2  correlation coefficient of the linear regression 
RSD  relative standard deviation 
sbb  standard deviation between bottles 
SD  standard deviation 
SDS  sodium dodecyl sulfate 
swb  standard deviation within bottles 
SI  International System of Units 
TM  target material 
TF  transfer factor 
TRIS  tris(hydroxymethyl)aminomethane 
TRF  transferrin 
TTR  transthyretin (also called prealbumin) 
U  expanded uncertainty 
ubb relative standard uncertainty related to the between-bottle heterogeneity 
u*bb standard uncertainty related to the between-bottle heterogeneity that can be 
hidden by the method repeatability 
uc  combined relative standard uncertainty 
ucal  relative standard uncertainty of the calibrant 
uchar  relative standard uncertainty related to the characterisation 
ults relative standard uncertainty related to the long-term stability of the material 
usts relative standard uncertainty related to the short-term stability of the material 
USNRP United States National Reference Preparation 
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1 Introduction and design of the project 
1.1 Background: need for the CRM 
Serum proteins levels are important measurands in clinical chemistry. The measurement of 
their concentrations is used in routine medical evaluations and in a large number of specific 
indications, and can be performed repeatedly without (major) injury to the patient.  
The immunoassays used for serum protein measurements are capable of a high degree of 
sensitivity and specificity, and are convenient in a clinical setting because they give fast 
results. They are based on the fact that when antigens (serum proteins) and specific 
antibodies are brought together they form complexes or aggregates that scatter incident 
light. The scattering of the light is measured by turbidimetry (measuring the reduction of light 
passing through a reaction mixture) or nephelometry (measuring the light scattered by a 
reaction mixture). The signal is dependent on a large number of factors such as antibody 
specificity, reaction kinetics and equilibria, multimeric state of the proteins, complex matrix 
effects, etc. The quantification with immunoassays is therefore entirely dependent on the 
comparison of the results with those obtained with a calibrant.  
The EU Directive on In Vitro Diagnostic Medical Devices (IVD-MD) (Directive 98/79/EC) 
requires traceability of calibrants and control materials to reference measurement 
procedures and/or reference materials of higher order. 
The requirements for a calibrant are that the assigned values are metrologically traceable, 
and accompanied by an uncertainty statement. The stability and homogeneity with respect 
to all the certified properties must be verified, and the calibrant must be commutable, i.e. 
resemble the patient samples [1]. These issues are particularly challenging for serum 
proteins, as they form a mixture of interacting proteins with different isoforms and 
complexes.  
In 1989 the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) 
began the processing, characterisation, and calibration of a secondary matrix reference 
material for human serum proteins. In 1993 the Bureau Communautaire de Référence 
released the resulting CRM 470 (later transformed to ERM-DA470), certified for 15 proteins 
[2]. The protein concentration measurements were calibrated with pure proteins for 
transthyretin (TTR), α1 acid glycoprotein (orosomucoid, AAG), α1 antitrypsin (α1-protease 
inhibitor, AAT), transferrin (TRF), and α1 antichymotrypsin (ACT), with the matrix material 
USNRP 12-0575C [3] for albumin (ALB), ceruloplasmin (CER), α2 macroglobulin (A2M), 
haptoglobin (HPT), complement 3c (C3c), complement 4 (C4), immunoglobulin A (IgA), 
immunoglobulin G (IgG), and immunoglobulin M (IgM) and with the 1st International Standard 
CRP 85/506 for C-reactive protein (CRP).  
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After the release of ERM-DA470 IVD manufacturers began referencing their calibrants and 
controls to the material, and the among-laboratory variances for assays of serum proteins 
became substantially lower for most of the proteins certified in ERM-DA470 [4, 5]. 
The present material has been produced to replace ERM-DA470 when that will be 
exhausted.  
1.2 Choice of the material 
The requirements for a material to be used as a reference material for serum protein 
immunoassays are, next to requirements for homogeneity, stability, traceability and 
commutability: 
 the concentration of the proteins in the final material should be high enough so that 
dilutions of the material can cover the relevant part of the measurement interval of 
the assays 
 the material should be optically clear. This property is important, as most clinical 
immunoassays use optical detection methods. This means that the material must 
have a low content of lipids and lipoproteins 
 there must be continuity of the measurement results from assays calibrated against 
consecutive reference materials. This is an important issue in clinical chemistry, as 
the use of reference ranges and decision limits requires that measurement results 
are comparable over longer time scales 
For most proteins certified in ERM-DA470, the material is sufficiently commutable to lead to 
a considerable reduction of inter-assay variances. Therefore it was decided to produce the 
new material according to procedures similar to those applied for ERM-DA470.  
1.3 Design of the project 
Serum was produced from blood collected in 6 blood collection centres according to a 
procedure ensuring that it was obtained from healthy donors, and that the lipid content of the 
serum was low.  
Two pilot batches were produced, one spiked with only CRP and one spiked with CRP and 
β2 microglobulin (B2M). The pilot batches were used to verify that the processing procedures 
resulted in material with the required properties (homogeneity, stability, commutability of 
B2M, optical clarity of the material). On that basis it was decided to further process the main 
part of the serum, and to spike the material with both CRP (from pleural fluids) and 
recombinant B2M.  
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The serum was processed in 5 batches, and then pooled, spiked with B2M and CRP and 
filled into vials (1 mL serum per vial). The serum was lyophilised in the vials and afterwards 
stored at -70 °C. 
The homogeneity and stability of the material were assessed for 14 proteins: A2M, AAG, 
AAT, ALB, B2M, C3c, C4, CER, HPT, IgA, IgG, IgM, TRF, and TTR. Compared to ERM-
DA470, ACT was not certified in the new material. B2M was added to the list of proteins in 
order to allow for its certification later on. For CER and CRP no values were assigned to the 
material during this certification campaign. 
The material was characterised for 12 proteins by using the reference material (ERM-
DA470) as calibrant. This was achieved using a value transfer protocol that can be 
considered as reference procedure [6]. In the so called closed value transfer procedure 6 
dilutions of the calibrant (ERM-DA470) and 6 dilutions of ERM-DA470k/IFCC are measured 
against the usual instrument calibrant, and the concentration of the target material is 
determined from the ratio of the slopes of the regression lines (measured concentration 
versus dilution). In the open value transfer procedure ERM-DA470 is used as a calibrant in 
the instrument, and the 6 dilutions of the target material are measured directly against 
different dilutions of that calibrant. The concentration of the target material is determined 
using the slope of the regression line (interpolated concentration versus dilution). 
The techniques used to measure the protein concentrations were nephelometry, 
turbidimetry, and for ALB also visible spectrometry. The measurements were performed with 
different platforms (i.e. instruments; Abbott Architect, Beckman Immage, BN II and BN 
ProSpec, different Hitachi instruments, Eiken LX 2200, Olympus AU640, Roche Integra) and 
reagents. In total 18 laboratories participated in the value assignment, 4 using open value 
transfer procedures, 12 using closed value transfer procedures, and 2 using both open and 
closed procedures (see Section 6.1). The majority of the characterisation measurements 
were either done under an ISO/IEC 17025 accreditation or within the scope of an ISO 13485 
quality system. Documented evidence of the technical competence and applied document 
control was obtained from the remaining laboratories. 
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2 List of participants 
 
Provision of serum and proteins 
Asahikawa Medical College (JP) 
Azienda Ospidaliera Policlinico Modena (IT) 
Blutspendedienst SRK Bern (CH) 
Centre de Transfusion Sanguine Liège, Service du Sang de la Croix-Rouge de Belgique 
(BE) (accred. ISO 15189 BELAC 331-MED) 
Centre for Amyloidosis and Acute Phase Protein, UCL Division of Medicine, London (GB) 
Dade Behring Marburg GmbH - A Siemens Company, Marburg (DE) 
Hralec Kralove University Hospital (CZ) 
Università degli Studi di Pavia (IT) 
 
Characterisation and processing of the serum 
Dade Behring Marburg GmbH - A Siemens Company, Marburg (DE) (certified ISO 13485 
TÜV Rheinland Product Safety GmbH SX 60014517 0001)  
Universitetssjukhuset I Lund (SE) (accred. ISO/IEC 17025 SWEDAC 1424) 
 
Stability and homogeneity studies 
DAKO Denmark, Glostrup (DK) (certified ISO 13485 UL A12312) 
Dade Behring Marburg GmbH - A Siemens Company, Marburg (DE) (certified ISO 13485 
TÜV Rheinland Product Safety GmbH SX 60014517 0001) 
Institute for Reference Materials and Measurements (IRMM), Joint Research Centre, 
European Commission, Geel (BE) (Accred. ISO Guide 34 BELAC 268-TEST) 
Olympus Life and Materials Science, Clare (IE) (certified ISO 13485 TÜV Rheinland Product 
Safety GmbH SX 60021010 0001) 
 
Characterisation 
Abbott Diagnostics, Irving (US) (certified ISO 13485 UQA 0103128/B) 
Centro Interdipartimentale sulla Riferibilità Metrologica in Medicina di Laboratorio (CIRME), 
Università Degli Studi di Milano (IT) 
Beckman Coulter, Brea (US) (certified ISO 13485 NSAI MD 19.0779) 
Dade Behring Marburg GmbH - A Siemens Company, Marburg (DE) (certified ISO 13485 
TÜV Rheinland Product Safety GmbH SX 60014517 0001) 
DAKO Denmark, Glostrup (DK) (certified ISO 13485 UL A12312) 
Denka Seiken, Tokyo (JP) (certified ISO 13485 TÜV Japan Ltd SD 951 05 3207) 
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Eiken Chemical Co., Tokyo (JP) (certified ISO 13485 TÜV Management Service GmbH Q1N 
05 10 56541 004) 
Foundation for Blood Research (FBR), Scarborough (US) 
Klinisk Kemi Malmö, Lunds Universitet (SE) (accred. ISO/IEC 17025 SWEDAC 1340) 
Kreiskliniken Altötting-Burghausen (DE) 
Laboratoire d'Immunologie, Centre Hospitalier Lyon-Sud (FR) 
Laboratorio di Biotecnologie e Tecnologie Biomediche, Policlinico San Matteo, Pavia (IT) 
Medical Biological Laboratories Co., Nagano-Ken (JP) (certified ISO 13485 SGS 
GB06/69985) 
Nitto Boseki, Fukushima (JP) (certified ISO 13485 SGS GB06/68575) 
Odense Universitetshospital (DK) 
Olympus Life and Materials Science, Clare (IE) (certified ISO 13485 TÜV Rheinland Product 
Safety GmbH  SX 60021010 0001) 
Protein Reference Unit, St. Georges Hospital, London (GB) 
Roche Diagnostics GmbH, Penzberg (DE) (certified ISO 13485 TÜV SÜD Q1N 07 08 45096 
003) 
 
Data analysis 
Acomed Statistik, Leipzig (DE) 
Andrew M. Johnson, Greenboro (US) 
Institute for Reference Materials and Measurements (IRMM), Joint Research Centre, 
European Commission, Geel (BE) (Accred. ISO Guide 34 BELAC 268-TEST) 
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3 Processing 
3.1 Preparation of the serum 
The starting material for the reference material was the serum prepared from the blood of 
healthy donors, collected at 6 different blood collection centres.  
Selection of the donors: Donors with clinical diagnoses of diabetes mellitus, jaundice, high 
blood pressure, heart, lung or kidney disease, pregnant women and top performance 
athletes were excluded. Samples with high cholesterol or triglyceride concentration were 
rejected. Donations from subjects with hepatitis and human immunodeficiency virus (HIV) 
infections were excluded, as well as donors with clinical evidence of bacterial infections. 
Serum collection protocol: 400 – 500 mL whole blood was withdrawn from each blood donor, 
expected to give an average serum volume of 180 mL (140 – 220 mL). For donors from 
Japan the volume of blood withdrawn was between 200 and 300 mL.  
 
The following protocol was applied for preparing the serum: 
a) Pre-prandial blood (tourniquet used) (the blood collected in Germany was not strictly pre-
prandial, but a very stringent selection was made on the transparency of the serum). 
b) Collection into a dry bag or a polymer bottle, not containing any additives or 
anticoagulants (such as Baxter, Fenwal) 
c) Clotting at room temperature for 3 - 4 hours 
d) Centrifugation of the bag in a centrifuge bucket or the bottle at 2200 g for 20 min 
e) Separation of the serum from the clot 
f) Freezing of the serum between -70 and -80 °C 
g) Transport of the serum to the IRMM on dry ice, storage at -70 °C. The serum produced in 
the Czech Republic was briefly stored at -30 °C before being shipped on dry ice 
 
Tests of the serum: The blood banks tested the serum for HIV 1+2, HBV or HBsAg, and 
HCV. Monoclonal gammopathies were detected by gel electrophoresis.  
6 donations were discarded because of the presence of monoclonal components, and 10 
donations were discarded because their rheumatoid factor (RF) concentration was above 30 
IU/mL (Table 1). 390 donations, of which 96 originated from female donors, were fulfilling the 
inclusion criteria, and were released for further processing. 
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Table 1: Summary information on the collected serum. In case certain donations had to be 
excluded, the parenthesised numbers indicate how many male and female donations are 
fulfilling the inclusion criteria. 
Collection centre  Donation period No. Male Female 
RF > 30 
IU/mL 
Monoclonal 
components 
Final 
No. 
Blutspendedienst 
SRK Bern AG (CH) 12/2006 80 78 (73) 2 (1) 3 3 74 
Hradec Králové 
University Hospital 
(CZ) 
11-
12/2006 80 64 (62)* 16 (16) 0 1 78 
Croix Rouge de 
Belgique, Liège 
(BE) 
10/2006 
to 
01/2007 
101 58 (57) 43 (42) 0 2 99 
Dade Behring 
Marburg GmbH (DE) 10/2006 60 46 (44) 14 (13) 3 0 57 
Asahikawa Medical 
College (JP) 
09/2006 
to 
01/2007 
 
26 14 (13) 12 (11) 2 0 24 
Policlinico Modena 
(IT) 
12/2006 
to 
02/2007 
60 46 (45) 14 (13) 2 0 58 
* one sample lost due to a leaking container 
 
3.2 Processing of the serum 
Overview of the procedure 
The processing procedure is summarised in Fig. 1. It followed largely that used for CRM 470 
(ERM-DA470) [2]. The major differences were that after the delipidation step a dialysis 
membrane with a cut-off of 10 kDa was used instead of 12-14 kDa, that no sodium azide 
was added to the serum before the pooling of the individual donations, and that the final 
sodium azide mass concentration was kept below 1 g/L. 
The serum donations from each collection centre were pooled and processed as collection 
centre pools so as to remove particulate matter and lipids, and to achieve a uniform degree 
of 'maturation' of the serum. As the batch from Japan was small it was processed together 
with the serum from Italy. The serum from different collection centres was then pooled, and 
sterile filtrated after addition of preservatives (sodium azide, aprotinin and benzamidine 
hydrochloride) and before the filling and lyophilisation.  
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Figure 1: Overview of the processing of the serum.  
 
3.2.1 Preparation of pools per collection centre 
Donations fulfilling the criteria were processed as follows: 
• thawing overnight at 2 - 8 °C 
• determination of the volume of each donation 
• pooling of all accepted donations of the same collection centre 
• addition of sodium azide (Merck, Darmstadt, DE) to a final concentration of 
7.7 mmol/L (approximately 0.5 g/L) 
• removal of 1/8th of the volume of each pool for verification and testing purposes and 
storage in 50 mL plastic tubes at below -70 °C 
• removal of aliquots for the measurement of cholesterol, triglycerides, apolipoprotein 
A-I, apolipoprotein B, total protein (Biuret reaction) and for the concentration 
measurement and physicochemical analysis of selected proteins  
 
The material is now in State A 
Thawing+pooling 
Sodium azide added 
 State A 
Conversion of C3 to C3c 
Delipidation 
Diafiltration  
 State B 
Addition of HEPES, 
aprotinin, sodium azide, 
benzamidine 
Sterile filtration  
 State C 
Pooling 
Spiking 
Sterile filtration 
 
BE CH CZ IT JP DE 
Pool
Testing of spiking 
B2M commutability study 
Stability study  
Trial value assignment 
Pilot studies 
Pooling 
Addition of aprotinin, 
sodium azide, 
benzamidine 
Spiking 
Sterile filtration 
 
Filling 
Lyophilisation 
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Conversion of C3 to C3c 
• adjustment of pH to 7.2 ± 0.1 with saturated 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) buffer (Calbiochem, Merck Biosciences, 
Schwalbach, DE) 
• addition of magnesium acetate tetrahydrate, final concentration 20 mmol/L (Merck, 
Darmstadt, DE) 
• adjustment of the solution to 37 °C  
• addition of Inulin (Sigma Aldrich, Milwaukee, US) to a final mass concentration of 
0.2 %  
• stirring for 2 hours at 37 °C 
Delipidation with Aerosil 
• adjustment of inulin-treated pool to pH 8.5 ± 0.1 with a saturated 
tris(hydroxymethyl)aminomethane (TRIS) solution (Sigma-Aldrich, Milwaukee, USA) 
• addition of sodium chloride (crystalline; Merck, Darmstadt, DE) to a final 
concentration of 50 g/L while stirring constantly 
• calculation of the required amount of Aerosil 200 (Degussa, Frankfurt, DE) based on 
the total protein concentration of the pool before the C3 conversion (430 mg 
Aerosil / g total protein) 
• gradual addition of Aerosil while stirring and constantly monitoring and if necessary 
adjusting the pH to 8.5 ± 0.1 
• continued slow stirring for another 30 min 
• removal of Aerosil (Degussa, DE) and protein precipitates by centrifugation for 30 
min at approx. 10000 x g using 500 mL centrifugation bottles 
• determination of the total volume of the clear supernatant  
• determination of the concentrations of cholesterol, triglycerides and apolipoproteins 
A-I and B to verify the successful lipid removal 
Sterile filtration and diafiltration 
• filtration of the supernatant using a 0.45 µm Sartobran P filter (Sartorius, Göttingen, 
DE) to remove small particles interfering with the following diafiltration  
• diafiltration (Centrasette with Omega membrane with a molecular weight cut-off of 
10000 Dalton; Pall, Hauppauge, US) using an isotonic sodium chloride solution to 
remove TRIS and Aerosil-derived free silica; this step combines buffer exchange and 
adjustment to the desired volume 
• removal of aliquots for the measurement of total protein and for the measurement 
and physicochemical analysis of selected proteins  
Material is now in State B 
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Preservation and sterile filtration 
• adjustment of the pH with saturated HEPES solution to 7.2 ± 0.1 
• addition of sodium azide to a final concentration of 14.6 mmol/L (0.95 g/L) 
• addition of aprotinin to 80000 KIU/L (8 mL Trasylol 500000 KIU/L, Bayer, 
Leverkusen, DE) 
• addition of benzamidine hydrochloride monohydrate (Merck, Darmstadt, DE) to a 
final concentration of 1 mmol/L 
• sterile filtration using a Sartopore 2 filter (0.2 µm) (Sartorius, Göttingen, DE) 
• sterile removal of aliquots for the measurement of total protein and for the 
measurement and physicochemical analysis of the proteins to be certified 
• sterile removal of 150 mL of the DE, CZ and BE pools; these aliquots were stored 
below -70 °C until processing of the pilot batches 
The material is now in State C.  
Until processing of the final pool the collection centre pools were stored below -70 °C. 
Protein concentration measurements: Throughout the processing, the concentrations of the 
proteins to be certified and of apolipoprotein A-I and B were determined by 
immunonephelometry (double determinations) on a BN ProSpec or BN II System using 
reagents, standards and controls of the Dade Behring Marburg GmbH.  
Total protein determination: Determination of total protein was done according to the Biuret 
method using pure human serum albumin (internal Dade Behring product) for calibration, 
solutions and chemicals were from Merck (Darmstadt, DE) or Sigma-Aldrich (Milwaukee, 
USA). 
Lipids: The cholesterol concentration was measured using the cholesterol CHOD-PAP Kit 
and triglycerides with the Triglycerides GPO Kit (Roche Diagnostics, Mannheim, DE). 
Physicochemical structure of the plasma proteins: The integrity of the proteins during 
processing was studied using several methods: 
• 2-dimensional immunoelectrophoresis according to Clarke and Freeman [7] 
• non-reducing sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and subsequent immunoblotting (DE, CZ and BE pools only) for C3/C3c, C4, 
AAT and CER 
• native PAGE  
• 2-dimensional electrophoresis.  
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3.2.2 Preparation of the combined pool 
 
Preparation of CRP and B2M  
463 mL of a purified human CRP solution (mass fraction 97 % of total protein; mass 
concentration 3.88 g/L) was used. The material was stored below -70 °C and thawed in a 
water bath at 37 °C with occasional turning. Before spiking the pool, the CRP solution was 
gently mixed while avoiding any turbulence. The starting material for B2M was lyophilised 
purified recombinant protein. 
 
Preparation of the final pool 
• thawing of all 5 separate pools (2 to 3 days) 
• pooling  
• sterile removal of aliquots for the measurement of B2M and CRP, and for the 
physicochemical analysis  
• preparation of CRP solution as described 
• slow addition of the total amount of the CRP solution (463 mL) while constantly 
stirring 
• reconstitution of recombinant B2M in sterile water  
• addition of B2M to the pool to a final concentration of approximately 2.6 mg/L (total 
amount added 65 mg) 
• pH adjustment with saturated HEPES solution (pH 7.2 ± 0.1) 
• sterile filtration (0.2 µm) 
• sterile removal of 3.5 L serum for storage as liquid frozen material (in ampoules 
containing 1 mL serum each, stored below -70 °C) 
• sterile removal of aliquots for further analysis, including sterility testing 
• analysis of liquid and lyophilised material (total protein, measurement of the 
concentration of and physicochemical analysis of the proteins to be certified)  
 
3.2.3 Processing control 
Pools per country of origin 
Total protein concentration: In line with the protocol of the preparation of the original ERM-
DA470 only pools with a total protein concentration between 60 and 80 g/L were considered 
to qualify as starting material for processing, and the Aerosil treated pools should be 
adjusted to between 55 and 75 g/L. As shown in Table 2, the total protein concentration of 
the pools was between 69 and 77 g/L in State A and between 64 and 69 g/L in State C, i.e. 
within the defined tolerance limits. 
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Table 2: Total protein concentration (Biuret method) and volumes of pools at different 
processing stages 
 
 State A State B State C 
Collection 
centre pool 
Volume 
[L] 
[total protein] 
[g/L)] 
Volume 
[L] 
[total protein] 
[g/L] 
Volume 
[L] 
[total protein] 
[g/L] 
DE 10.51 69.0 8.8 68.4 8.63 65.8 
CZ 11.21 72.0 9.3 68.1 9.13 69.2 
CH 11.21 77.3 9.4 67.7 9.43 68.8 
BE 15.22 69.9 
JP  2.62 73.7 
14.0 66.9 14.04 63.8 
IT  8.91 71.1 7.0 70.9 7.1 69.4 
1 starting volume for processing (1/8th of the volume of the pool was stored for other purposes) 
2 starting volume for processing (1 L of BE-Pool and 200 mL of JP-Pool stored for other purposes) 
3 final volume after processing and subtraction of 150 mL used for pilot batches 
4 final volume after processing and subtraction of 200 mL for pilot batches 
 
C3 conversion: Conversion of C3 to C3c was verified with 2-dimensional 
immunoelectrophoresis (see Fig. 2) using aliquots of the pool before starting the processing 
(State A), and after sterile filtration (State C). In the A State a small amount of C3 was 
already converted to C3c. Only in the serum from Japan and Belgium the conversion had 
progressed to a higher extent, probably due to different time schedules in the blood 
collection process. 2-dimensional immunoelectrophoresis results of the material in State C 
demonstrate that the major part of C3 was converted to C3c. 
 
 
Figure 2: Crossed immunoelectrophoresis measurement profiles of C3/C3c, C4, CER, and AAT 
in the serum from the Czech Republic, before (State A, left) and after (State C, right) 
maturation. 
C3/C3
c  
C3/C3C C
CE CEAAT AAT 
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Delipidation: For the delipidation by the Aerosil treatment to be considered successful, 
relative mass concentrations of cholesterol and apolipoprotein B should be reduced to 1 % 
of the concentration in the starting material. The relative mass concentrations for 
triglycerides and apolipoprotein A-I should be below 15 % and 20 % of the starting material, 
respectively. As shown in Table 3, these criteria were fulfilled for all individual pools. The 
reduction of the blank value obtained by measuring the signal of undiluted sample using a 
BN100 System also demonstrated the effective removal of lipoproteins. 
 
Table 3: Lipoproteins before processing and after Aerosil treatment1 
 State A State B State C 
Pool 
Chole-
sterol 
[mg/L] 
Trigly-
cerides 
[mg/L] 
Apo A-I 
[mg/L] 
Apo B 
[mg/L] 
Blank 
value 
[Bit] 
Chole-
sterol 
[mg/L] 
Trigly-
cerides 
[mg/L] 
Apo 
A-I 
[mg/L] 
Apo B 
[mg/L] 
Blank 
value 
[Bit] 
DE 1627 1189 1555 806 3497 ND 95.5 ND ND 55 
CZ 1788 2266 1565 931 1992 ND 56.4 ND ND 75 
CH 1760 920 1715 874 3082 11.5 95.5 ND ND 103 
BE 1903 767 1620 870 1553 
JP 1875 1158 1595 783 >2 
ND 8.3 ND ND 99 
IT 1846 725 1645 842 2498 5.8 8.3 ND ND 101 
1 when the concentration is below the limit of detection this is marked by ND (not detectable) 
2 exceeds measuring interval (0-4096 Bit) 
 
Concentration of 14 serum proteins: The protein loss caused by the delipidation process was 
compensated to a certain extent by reducing the volume by 19 % by diafiltration, so that the 
mass concentrations of most proteins were found within 90 to 100 % of the starting values 
(Table 4). Higher losses were observed for IgM, C4 and CER due to the known affinity of 
these proteins to Aerosil. The B2M concentration decreased similarly. Nevertheless, the 
concentration of B2M was adjusted in the final pool with recombinant material. 
 
Preparation of the combined pool 
 
Sterility test: The sterility of the material was verified by inoculating Casein Soy (CASO) 
Bean Digest Broth with the sterile filtrated pool, and streaking it out on CASO agar, Blood 
agar and McConkey agar (Institut für Medizinische Mikrobiologie und Krankenhaushygiene, 
University of Giessen and Marburg, DE). No growth was observed on the selected media 
after five days, and the pool was released for filling. 
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Homogeneity of the filling volume: The consistency of the filling volume was determined 
during the filling process by taking samples (4 consecutive vials each) at regular intervals 
(approx. every 15 min). Altogether 24 samples consisting of 4 vials each were taken. The 
average mass of the liquid filled into these 96 vials was 1004 mg with a standard deviation 
(SD) of 5 mg. 
 
Residual moisture and dry mass: The dry mass of the vial contents and the residual moisture 
were determined in parallel. To determine the dry mass, the mass of a vial was determined 
before and after removal of the vial content. The remaining moisture in the lyophilised 
material was analysed by Karl Fischer titration [8]. 10 vials each were analysed from the 
beginning, middle and end of the filling process (N=30). The measurement results and the 
standard deviation (SD) and relative standard deviation (RSD) are: 
average dry mass  76.0 mg  average residual moisture 4.3 mg/g 
interval  74.0 – 78.0  interval   3.6 – 6.0 mg/g 
SD   0.9 mg   SD    0.6 mg/g 
RSD   1.2 %   RSD    14 % 
The average dry mass of the new material is similar to that in ERM-DA470 (76.0 mg versus 
71.8 mg), whereas the average residual moisture is lower in the new material (4.3 mg/g 
versus 5.7 mg/g), but similar to the values of the pilot batches (4.3 mg/g).  
 
Blank values: The blank value for the final pool before sterile filtration was 93 Bit (detector 
values), after sterile filtration 84 Bit. The final preparation had blank values of 204 Bit (liquid) 
and 183 Bit (lyophilised and reconstituted). According to the specifications for the platform 
concerned an empty cuvette is considered adequately inserted and optically clear if the 
scattered light gives a signal between 20 and 600 Bit. Therefore these results show that the 
material is optically clear. 
 
Mass density measurements: The mass density of the reconstituted ERM-DA470k/IFCC, the 
liquid frozen processed serum, and reconstituted ERM-DA470 were measured with an Anton 
Paar densitometer (Graz, AT), and found to be 1.0221, 1.0236 and 1.0234 g/mL, 
respectively, at 20 °C. As the difference between the density of ERM-DA470 and the density 
of ERM-DA470k/IFCC is negligible compared to the uncertainties of the certified values no 
systematic density correction was applied to the transfer factors.  
 
Protein concentration measurements on the final preparation: The concentrations of the  
selected serum proteins were analysed on BN ProSpec systems. Lyophilised materials were 
reconstituted according to the procedure described in section 9. Liquid and lyophilised and 
reconstituted materials were measured in triplicate in the same analytical series. The final 
pool was measured in duplicate before and after sterile filtration 
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The results show that there is a relative loss of 4 - 8 % of measured protein concentration 
upon lyophilisation and reconstitution for most proteins. This is mostly due to a dilution 
effect, as the volume of water removed by lyophilisation of a 1.0 mL serum sample is less 
than 1.0 mL, and the material is reconstituted with 1.0 mL water.  
 
 
Table 4: Approximate protein concentrations and optical clarity at the final processing stages 
 Protein mass concentration (n = 3) [g/L]1 
Protein Sterile filtrated  final pool 
After filling 
 
Reconstituted 
lyophilised 
material 
Relative 
decrease in 
concentration by 
lyophilisation 
[%] 
  A2M 1.52 1.52 1.43 5.9 
  AAG 0.640 0.696 0.649 6.8 
  AAT 1.16 1.16 1.09 6.0 
  ALB 39.6 42.0 39.4 6.2 
  B2M1 2.59 2.79 2.63 5.7 
  C3c 1.08 1.07 1.02 4.7 
  C4 0.172 0.184 0.167 9.2 
  CER 0.187 0.186 0.172 7.5 
  HPT  0.940 0.979 0.921 5.9 
  IgA 1.98 1.96 1.85 5.6 
  IgG 10.9 10.6 9.89 6.7 
  IgM 0.773 0.777 0.739 4.9 
  TRF  2.50 2.47 2.37 4.0 
  TTR 0.217 0.236 0.219 7.2 
Total protein 66.5 63.3 58.2 8.1 
Blank value (Bit) 84 204 183  
1[mg/L] for B2M  
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3.3 Filling, lyophilisation, capping and labelling 
1 mL serum was filled into each vial under clean-room conditions. Uncoloured threaded and 
siliconised glass vials were used.  
Within one hour after filling the lyophilisation program was started. Closing of the bottles 
using grey rubber stoppers was performed under a low-pressure nitrogen atmosphere.  
Capping and labelling was performed using red screw caps. Due to the large number of vials 
this step had to be done on two machines in parallel.  
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4 Homogeneity  
4.1 Homogeneity 
The homogeneity of ERM-DA470k/IFCC was verified by measuring the proteins in triplicate 
in 40 vials taken randomly over the whole batch. The measurements were performed with a 
BN ProSpec and Dade Behring reagents, or with a Hitachi 917 instrument and DAKO 
reagents, depending on the protein. The protein concentrations were corrected for the mass 
of the water used to reconstitute each sample. 
Grubbs tests were performed to detect outlying individual results as well as averages 
measured for each vial. For HPT, IgM, and TRF outliers (one each) were found at the 99 % 
confidence level, but these were retained in the analysis. 
Regression analyses were used to evaluate potential drifts in results related to the analysis 
sequence or to the filling sequence. Small but significant trends (at the 99 % confidence 
level) were observed for A2M, AAT, C3c, and CER. The homogeneity measurements had 
been done in such a sequence that trends due to analysis sequence and filling sequence 
could still be confounded. The 6 months stability data (see Section 5.2) had been measured 
in such a manner that these trends could be separated, and the analysis of these data 
showed that there is no trend in function of the filling sequence. Therefore the trend in the 
results of the homogeneity measurements is due to a drift in function of the analytical 
sequence.  
It was furthermore checked whether the data followed a normal and unimodal distribution 
using normal probability plots and histograms respectively. The individual data and the bottle 
averages were unimodal for all proteins, although some deviations from normality were 
observed.  
ANOVA statistics were used to calculate the between bottle standard deviation (sbb) and the 
maximum standard uncertainty related to the inhomogeneity that can be hidden by the 
method repeatability (u*bb), using the formulas: 
 
 
       
(MSbb = mean sum of squares between bottles; MSwb = mean sum of squares within bottles; 
n = number of replicates; dfwb = degrees of freedom within bottles) 
Both values were converted into relative uncertainties (Table 5). The larger of both values 
was included into the calculation of the overall uncertainty of the certified values (Section 
7.1). 
n
MSMSs wbbbbb
−= 4wb*bb 2
wbdfn
MSu ⋅=
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Table 5: Relative between bottle homogeneity1 
Protein Relative between bottle heterogeneity (sbb,rel) [%] 
Relative maximum hidden 
heterogeneity (u*bb, rel) [%] 
    A2M NC 0.517 
    AAG NC 0.484 
    AAT 0.675 0.527 
    ALB NC 0.612 
    B2M NC 0.666 
    C3c NC 0.557 
    C4 NC 0.418 
    CER NC 0.672 
    HPT 0.637 0.413 
    IgA NC 0.340 
    IgG NC 0.425 
    IgM 0.745 0.573 
    TRF NC 0.498 
    TTR 1.153 (0.880)2 0.520 (0.144)2 
1) When MSbb was smaller than MSwb, sbb could not be calculated. Those cases  
are marked as NC (non-calculable). 
2) Values obtained on a Hitachi 917 using DAKO reagents are given in parentheses. 
 
4.2 Minimum sample intake for analysis 
The reconstituted material forms a clear solution, and as a true solution is not expected to 
have any relevant heterogeneity in protein concentration at sample intakes even below nL 
volumes. The sample intakes of homogeneity studies on the material measured with a 
Hitachi 917 platform were between 2 and 24 μL, depending on the protein. For all the 
proteins the standard deviation within a bottle (swb) is lower or equal to the expected method 
variability (data not given), so there is no indication of intrinsic heterogeneity or 
contamination at a sample intake of 2 μL.  
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5 Stability 
Short and long-term stability studies were carried out using an isochronous set-up [9] that 
consists of the simultaneous analysis of reference and test samples. For each study a 
defined set of samples was exposed for different periods of time to elevated temperatures 
and then brought back to the reference temperature (above liquid nitrogen or -70 °C). At the 
end of the study all samples were analysed for the concentrations of the proteins within one 
analytical run under repeatability conditions. The data were analysed by determining the 
regression line for the protein concentration in function of time, and determining whether it is 
significantly different from zero [10]. 
5.1 Short-term stability 
A short-term stability study was performed in order to assess the possible effect of transport 
at different temperatures on the stability of the material. The reference temperature was 
below -140 °C, as the reference samples were stored above liquid nitrogen. Test samples 
were kept for 0, 1, 2, and 4 weeks at -70, -20, 4, and 60 °C before being brought back to the 
reference temperature. For each combination of time and temperature 2 samples were 
analysed in triplicate. The samples were analysed for all proteins by turbidimetry using a 
Hitachi 917 platform (i.e. equipment) and DAKO reagents, except for IgM and B2M, which 
were analysed on an Olympus AU640. The values were corrected for the variable 
reconstitution volume. The results are shown in Table 6.  
Table 6: Short-term stability study: slope (b), test for significance of the slope (|b/ub|), and 
relative standard uncertainty after one week storage at the specified temperature usts 
 -70 °C -20 °C 
Protein b [(mg/L)/week] |b/ub| 
usts 
[%] 
b 
[(mg/L)/week] |b/ub| 
usts 
[%] 
A2M 2.4 1.1 0.15 0.8 0.5 0.13 
AAG 0.04 0.0 0.11 0.9 1.0 0.15 
AAT 2.6 1.5 0.14 -0.3 0.2 0.13 
ALB -61.0 0.9 0.17 -7.1 0.2 0.13 
B2M -0.0069 1.3 0.25 -0.0027 0.6 0.19 
C3c 2.3 1.9 0.12 1.3 1.1 0.12 
C4 -0.1 0.5 0.16 0.1 0.5 0.15 
CER 0.3 1.0 0.21 0.3 0.7 0.27 
HPT -0.1 0.1 0.12 2.0 1.7 0.14 
IgA 1.9 0.5 0.21 1.4 0.4 0.18 
IgG -2.6 0.2 0.16 -16.8 1.7 0.12 
IgM -1.7 0.6 0.35 -3.4 1.4 0.35 
TRF 5.2 1.7 0.14 1.3 0.4 0.14 
TTR -0.2 1.0 0.12 -0.3 1.0 0.13 
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Table 6 Continued 
 4 °C 60 °C 
Protein b [(mg/L)/week] |b/ub| 
usts 
[%] 
b 
[(mg/L)/week] |b/ub| 
usts 
[%] 
A2M 2.4 0.7 0.15 14.6 7.3 0.57 
AAG 1.3 1.4 0.15 -2.6 2.2 0.20 
AAT 0.2 0.13 0.13 -1.3 0.7 0.15 
ALB -100.0 2.0 0.15 -250.0 5.4 0.18 
B2M -0.0093 1.6 0.27 -0.0054 1.1 0.23 
C3c 1.7 1.4 0.12 1.6 1.1 0.15 
C4 0.2 1.0 0.14 5.3 13.3 0.58 
CER 0.1 0.3 0.24 7.6 15.2 0.67 
HPT 1.2 1.2 0.11 -0.5 0.4 0.15 
IgA 1.3 0.4 0.19 2.0 0.6 0.18 
IgG -17.0 1.6 0.13 -43.4 5.2 0.19 
IgM -3.0 1.1 0.35 0.9 0.4 0.30 
TRF 5.5 1.7 0.15 -5.8 1.4 0.18 
TTR -0.4 1.3 0.13 -0.1 0.3 0.14 
For each protein and temperature there were 24 measurements, or 22 degrees of freedom 
for the linear regression. The slope of the protein concentration in function of time is 
significantly different from 0 when the absolute value of slope b divided by its uncertainty ub 
(|b/ub|) is larger than t0.05, 22 = 2.07. When samples were kept at -70, -20 and 4 °C none of the 
slopes was significantly different from 0. However at 60 °C significant (at a 95 % confidence 
level) negative slopes were found for AAG, ALB, and IgG, and significant positive slopes for 
CER, C4 and A2M, although even at 60 °C the added uncertainties due to storage at this 
temperature for one week would be small. It was concluded from this study that the 
uncertainty due to degradation during dispatch is negligible, if the material is shipped with 
cooling elements.  
5.2 Long-term stability 
The ERM-DA470k/IFCC has been produced according to procedures that follow those for 
ERM-DA470 very closely. One of the reasons for doing so is that ERM-DA470 has proven to 
be stable for all proteins for which values were certified in the material. As the protein 
concentrations have been monitored in that material for over 14 years without detecting any 
instability it can be expected that ERM-DA470k/IFCC will also be stable over longer periods.  
A 6-months stability study was performed in order to confirm the stability of the material upon 
storage at -70 and -20 °C. The reference temperature was below -140 °C, as the reference 
samples were stored above liquid nitrogen. The test samples were kept for 0, 1, 2, 4, 5, and 
6 months at -70 and -20 °C. The samples were analysed by nephelometry, using a 
BN ProSpec. Each protein in each randomly selected vial was measured in triplicate, in 
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three separate runs. The values were corrected for the variable reconstitution volumes of the 
vials, and normalised to the run mean to correct for the evaporation of samples between 
runs. The measurements were divided by the protein concentration averaged over all the 
vials of that particular run and multiplied with the protein concentration averaged over all 
vials and all three runs. 
The results are shown in Table 7. For IgA, TRF, A2M, CER, IgM, HPT, and TTR there were 
54 measurements, or 52 degrees of freedom for each linear regression of each protein at 
each temperature. IgG, ALB, B2M, C3c, C4, AAT, and AAG were measured from a different 
set of vials. One of these vials was reconstituted incorrectly, and thus for these proteins 
there were 51 measurements per temperature, or 49 degrees of freedom. None of the 
slopes (protein mass concentration versus time) of any of the proteins was significantly 
different from 0 at a 99 % confidence level. At a 95 % confidence level the |b/ub| for C3c at 
-20 °C was just above the t0.05, 51=2.01. The uncertainty given for the long-term stability 
corresponds to the maximum uncertainty due to instability that could be hidden by the 
measurement variation after a period of 6 months. The results indicate that it is safe to store 
the material at either -20 or -70 °C. 
Table 7: Long-term stability study: slope (b), test for significance of the slope (|b/ub|), and 
relative standard uncertainty contribution ults due to storage for 6 months at the specified 
temperature 
 -70 °C -20 °C 
Protein b [(mg/L)/month] |b/ub| 
ults 
[%] 
b 
[(mg/L)/month] |b/ub| 
ults 
[%] 
  A2M -2.7 1.6 0.729 -1.6 1.2 0.557 
  AAG -0.3 0.8 0.355 -0.2 0.3 0.500 
  AAT 0.9 0.8 0.627 -0.5 0.4 0.635 
  ALB 61.7 1.8 0.540 51.6 1.4 0.556 
  B2M -1.1 0.3 0.824 -0.5 0.2 0.609 
  C3c -0.2 0.3 0.486 1.8 2.4 0.439 
  C4 -0.04 0.3 0.461 -0.04 0.3 0.482 
  CER -0.3 1.5 0.786 0.04 0.0 0.664 
  HPT -0.6 0.7 0.722 -1.0 0.9 0.573 
  IgA -4.1 1.7 0.788 -1.7 1.1 0.498 
  IgG 17.2 1.8 0.563 11.9 1.4 0.537 
  IgM 1.8 1.6 0.883 -0.4 0.3 0.919 
  TRF -3.4 1.1 0.800 -2.7 1.4 0.498 
  TTR -0.3 0.8 1.043 -0.4 1.3 0.751 
In parallel a 12 months stability study was performed on a pilot batch of serum processed in 
exactly the same manner as the final material, including the spiking with B2M and CRP. The 
reference temperature was -70 °C. The test samples were kept for 0, 2, 8, and 12 months at 
-20, 4, and 18 °C. The samples were analysed by turbidimetry, using a Hitachi 917 and 
DAKO reagents. Each protein in each randomly selected vial was measured in triplicate, in 
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three separate runs. The values were corrected for the variable reconstitution volumes of the 
vials.  
The results for -20 and 18 °C are shown in Table 8. For each protein and temperature there 
were 24 measurements, or 22 degrees of freedom for each linear regression. None of the 
slopes (protein mass concentration versus time) of any of the proteins was significantly 
different from 0 at a 99 % confidence level at -20 °C. At 18 °C significant slopes (at the 95 % 
confidence level) are found for AAG, AAT, CER, IgG, and TRF. The uncertainty given for the 
long-term stability corresponds to the maximum uncertainty due to instability that could be 
hidden by the measurement variation after a period of 12 months. The results indicate that it 
is safe to store the material at -20 °C for 12 months. 
Table 8: Long-term stability study: slope (b), test for significance of the slope (|b/ub|), and 
uncertainty ults added by the storage for 12 months at the specified temperature 
 -20 °C 18 °C 
Protein b [(mg/L)/month] |b/ub| 
ults  
[%] 
b 
[(mg/L)/month] |b/ub| 
ults 
[%] 
A2M 0.8 0.9 0.669 0.0 0.0 0.626 
AAG 0.1 0.3 0.632 -0.7 2.3 0.910 
AAT 0.4 1.0 0.410 1.5 2.5 1.062 
ALB -13 0.7 0.567 38 1.7 0.734 
B2M 0.1 0.0 2.012 -4.0 0.8 2.676 
C3c 0.1 0.3 0.445 -0.6 1.2 0.602 
C4 0.01 0.0 0.497 -0.2 2.0 1.149 
CER -0.004 0.0 0.880 0.3 3.0 1.640 
HPT 0.3 0.8 0.494 0.9 1.8 0.692 
IgA 0.0 0.0 0.357 -1.3 1.4 0.573 
IgG -0.3 0.7 0.615 -13.7 3.3 1.206 
IgM 0.4 1.3 0.562 -0.4 1.0 0.661 
TRF -1.2 0.9 0.646 -3.5 2.7 1.248 
TTR 0.1 1.0 0.592 -0.2 2.0 0.609 
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6 Characterisation 
6.1 General principles 
Values were assigned by calibration with the matrix certified reference material ERM-DA470 
(see Table 9) by value transfer procedures that minimise the effects of assay methods, 
calibration curve fitting and matrix differences [6]. The methods used for transferring values 
are validated, well established routine methods such as turbidimetry, nephelometry, and 
occasionally visible spectrometry. The laboratories used either of two different approaches, 
called the open and closed value transfer procedures. For both procedures measurements 
were performed over 4 days, with the independent reconstitution of the reference and target 
materials and preparation of dilutions on each of the four days. All reconstitutions and 
dilutions were verified by weighing, and the concentrations calculated from the masses 
rather than from the intended volumes. 
Table 9: Certified values and expanded uncertainties of the calibrant ERM-DA470 
Protein Certified value
1) 
[g/L] 
UCRM2) [g/L] Calibrant 
A2M 1.64 0.05 USNRP 12-0575C 
AAG 0.656 0.005 Pure protein 
AAT 1.206 0.011 Pure protein 
ACT 0.245 0.015 Pure protein 
ALB 39.7 0.8 USNRP 12-0575C 
C3c 1.091 0.027 USNRP 12-0575C 
C4 0.151 0.005 USNRP 12-0575C 
CER 0.205 0.011 USNRP 12-0575C 
CRP 0.0392 0.0019 1st Intl. Std. CRP 85/506 
HPT 0.893 0.009 USNRP 12-0575C 
IgA 1.96 0.04 USNRP 12-0575C 
IgG 9.68 0.010 USNRP 12-0575C 
IgM 0.797 0.023 USNRP 12-0575C 
TRF 2.45 0.006 Pure protein 
TTR 0.243 0.018 Pure protein 
1) When the material is reconstituted according to the specified procedure. The values are the 
unweighted means of 3-14 accepted mean values, independently obtained by 3-14 laboratories.  
2) The certified uncertainty is the half-width of the 95 % confidence interval of the mean defined in 
footnote 1). t-factors were chosen according to the t-distribution depending of the number of accepted 
sets of results. 
In the open value transfer procedure 6 dilutions of ERM-DA470 were used for calibrating the 
instrument, and 6 dilutions of ERM-DA470k/IFCC were assayed against this calibration. This 
procedure makes it possible to check for proportionality between the materials (in the assays 
for which they are intended to be used) by assessing the linearity and the intercept of the 
regression line, as these are measures of differences in matrix effect between the two 
materials. 
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The open transfer procedure was optimised separately for each platform participating in the 
value assignment, for each protein measured with that platform. The main parameter 
optimised was the dilution scheme. It was taken into account that dilutions done by the 
platforms should be avoided as much as possible (as these dilutions can not be corrected by 
more accurate weighings). On most platforms the option exists to provide 'pre-diluted' 
samples to the instrument, and to switch off the dilutions normally done automatically by the 
platforms. Further it was required that the interval of concentrations for the dilutions of the 
calibrant was at least 10 % broader than the expected concentration interval of the dilutions 
of the candidate reference material at the high and low end of this expected concentration 
interval. Proteins for which similar dilution schemes could be used were grouped, and 
common dilution schemes were developed for these groups of proteins. Finally it had also to 
be taken into account that for each material all six dilutions should be prepared from a single 
vial.  
In the closed procedure 6 dilutions of ERM-DA470 and 6 dilutions of ERM-DA470k/IFCC 
were assayed against the calibrants normally used by the laboratories. These calibrants are 
usually the ones provided by the companies selling the assay reagents, and are most often 
traceable to ERM-DA470. This procedure has in principle the disadvantage that the 
precision is lower, and that the proportionality of the materials can not be assessed directly. 
The presence of a matrix effect in either material will lead to non-linearity of the regression 
line for that material, and to a non-zero intercept. Here again dilution schemes were 
optimised for the different platforms, taking into account the working range of the assays, the 
requirement that all dilutions should be prepared from a single vial, and that the volumes of 
the dilutions be large enough to allow for all the measurements.  
20 laboratories participated in a trial run using the closed value transfer procedure. The trial 
run was aimed at testing that all the procedures linked to the value transfer (reconstitution, 
reporting of the results, etc.) were well controlled. Potential problems either in the 
procedures or in their application could be identified, and it was assured that all laboratories 
had a comparable level of performance. Some problems were detected during the trial run, 
but overall the results ranged from acceptable to very good for all participating laboratories. 
6.2 Performance of the value assignment measurements 
The laboratories were provided with detailed protocols and reporting sheets, as well as with 
vials of ERM-DA470, and ERM-DA470k/IFCC. Laboratories were asked to specify the 
platform and reagents used, and the order in which the measurements were performed. Both 
procedures required that the material was reconstituted the day before the measurements, 
according to the procedure described in the certificate of ERM-DA470 and ERM-
DA470k/IFCC. 
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For each of the 4 measurement days a new vial of the reference preparation and the target 
material was reconstituted and a new set of 6 dilutions of each prepared. 
Open value transfer procedure 
On each measurement day, 3 runs were performed. Each run was done with new 
calibrations using 6 dilutions of ERM-DA470. The 6 dilutions of ERM-DA470k/IFCC and the 
control material (which consisted of a separate dilution of ERM-DA470) were measured as 
samples. Each calibrant, target and control material dilution was measured in duplicate at 
each run. Laboratory 3 used a different procedure that had already been validated 
previously. According to their procedure all the dilutions are measured in triplicate, over 3 
days only, resulting in a slightly higher number of measurements. 
Closed value transfer procedure 
On each measurement day each of the 6 dilutions of ERM-DA470 and 6 dilutions of ERM-
DA470k/IFCC were measured in triplicate. The laboratories used one of three dilution 
schemes, depending on the assay intervals of particular proteins and on the volumes 
required for the measurements. The intended volume fractions of the candidate reference 
material and the calibrant in the dilution schemes are given in percent of the reconstituted 
material present in the dilutions. 
Scheme A:  40, 50, 60, 70, 80 and 100 % of the reconstituted material 
Scheme B1:  33.3, 40, 50, 60, 66.7 and 80 % of the reconstituted material 
Scheme B2:  25, 33.3, 40, 50, 66.7, 80 % of the reconstituted material 
6.3 Data analysis 
Principle of the analysis 
The aim of the value transfer is to determine for each protein the transfer factor (TF) 
TF = CT/CR (1) 
where CT and CR are the mass concentration of the protein in the target material (TM, ERM-
DA470k/IFCC) and in the calibrant (RM, ERM-DA470), respectively.  
Six different dilutions of the calibrant are prepared. The mass concentration of the specific 
protein in each dilution will be: 
CR(i) = FR(i) x CR  (2) 
where FR is the dilution factor of the RM and (i) denotes the different dilutions (i = 1 to 6). 
The concentrations of the specific proteins in the dilutions of the target material will be: 
CS(j) = FT(j) x CT (3) 
Where FT is the dilution factor of TM and (j) denotes the different dilutions of TM (j = 1 to 6). 
For the open value transfer procedure a calibration run is made, and the calibration curve is 
constructed by plotting the signals against the different dilutions of R. In a measurement run 
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the different dilutions of TM are assayed. The signals of these unknown test samples CS(j) 
are interpolated on the calibration curve, and are measured in relative concentrations of R: 
CS(j) = FR(j) x CR (4) 
A combination of (3) and (4) gives: 
CS(j) = FT(j) x CT = FR(j) x CR 
FR(j) = CT/CR x FT(j) (5) 
which is the equation of a straight line through the origin (y = TF x). 
The different dilution factors FR(j) obtained by interpolation are plotted against the different 
dilution factors FT(j) used for the initial dilution of T. Since all dilutions are controlled by 
weighing, the uncertainty of FT(j) is negligible compared to that of the measurement results. 
For the closed value transfer procedure the dilutions of the RM can not be used directly as 
calibrant. When the measured signals for the target material  
CS,T(j) = FT(j) x CT  
and for the RM  
CS, R(i) = FR(i) x CR  
are plotted against the dilutions FT(j) and FR(i) respectively, the TF = CT / CR can be derived 
as the ratio of the slopes of the respective linear regressions.  
Calculation of the dilutions 
The precision of the values for the dilutions were considerably improved by weighing all the 
liquids used for the reconstitution of the materials and for the preparation of the dilutions to a 
precision of at least 0.0001 g. 
The following mass corrections were applied: 
For the reconstitution: 
iM,
intended
iM, m
mf =  
Where mintended is the mass intended to be added (1.0000 g), and mM,i is the measured mass 
of the water added to the vial 
For eventual predilutions: 
iPD,iPR,
iPR,
iP, mm
m
f +=  
where mPR,i and mPD,i are the masses of the of the reconstituted material and of the diluent 
for the predilution 
 
For the dilutions:  
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iDD,iDM,
iDM,
ijD, mm
m
f +=  
for the dilution j of the material i, with mDM,i the mass of the reconstituted (eventually 
prediluted) material, and mDD,i the mass of the diluent for dilution j. 
The concentration cij (with c = m / V (mass / volume) and the unit g/L) of the proteins in the 
dilutions is calculated via: 
cij = c0i x fM,i x fP,i x fD,ij  
with c0i of the protein in material i, and cij the concentration of the protein in dilution j of 
material i. 
Determination of the transfer factors (TFs) 
For the open value transfer procedure the laboratories used the dilutions to construct the 
calibration curve directly. The values entered into their instrument for the concentrations of 
these dilutions were the values of the concentrations relative to the concentrations in ERM-
DA470, expressed in percent. The relative concentrations were corrected for the masses of 
the dilutions (and predilution if relevant).  
Then for each run, the laboratories measured the dilutions of the target material in triplicate. 
The measurement results Sijk (signal of the kth measurement of material i within dilution j, 
expressed in %) were plotted in scatter plots Sijk = f(cij) for the single measurements so as to 
evaluate outliers. Outliers were only rejected if there was a technical reason for doing so (a 
transcription error, wrong dilution, etc.). A linear regression was performed on the means of 
the Sijk in function of the concentration cij.  
The following specific acceptance criteria were applied for the open procedure: 
The mean control value (measured concentration of a particular protein in a control 
dilution of ERM-DA470 relative to the concentration in the control sample expected 
on the basis of the dilution, corrected for the mass values obtained by weighing) is 
within 1.00 ± 0.05 
For the closed value transfer procedure the laboratories measured the 6 dilutions of the 
target (Y1-Y6) and the reference material (X1-X6) in triplicate on each day. For both the 
reference and the target materials, single measurement results Sijk (signal of the kth 
measurement of material i within dilution j, in g/L) were plotted in scatter plots Sijk = f(cij) so 
as to evaluate outliers. For both the reference and the target material, a linear regression 
with intercept was performed on the means of the Sijk in function of the concentration cij. 
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The following analyses were performed on all data: 
- evaluation of the studentised residuals for the identification of outliers  
- testing for the homoscedasticity of the residuals (whether the variances are 
homogeneous) via a t-test 
- testing for normality (visual inspection and normal probability plot) 
- testing for linearity (visual inspection and evaluation of R2)  
- testing for outliers of the regression model according to the method of Lund [11] 
(only in case of homoscedasticity).  
- verification that the intercept ± 4 times the SD covers the origin.  
The TFs were calculated as the slope of the linear regression line for the open value transfer 
procedure, and as the ratio of the slopes of the linear regression lines for the candidate 
reference material and for the calibrant for the closed value transfer procedure.  
The following general acceptance criteria were applied to the datasets: 
1. The 95 % confidence intervals of the intercepts of the regressions of the calibrant 
and the target materials must be overlapping (closed datasets only). 
2. R2 of the regression must be above 0.97 for Immage data and above 0.98 for all 
other platforms 
3. Data from at least 4 dilutions must be available 
4. The completeness of data must be at least 50 % for the data for a particular 
protein on a particular day. Otherwise the data from that day are declared non-
valid 
5. At least two daily value assignments must be valid 
6. The day-to-day variation (RSD) of valid datasets for a particular protein and 
laboratory must be below 5 % (8 % for A2M)  
Rationale for the acceptance criteria: 
- Non overlapping confidence intervals of the intercepts of closed protocol regressions are 
either an indication of differing matrix effects or of quality problems of measurements 
resulting in scattering, both of which would result in non-valid TFs. 
- Overall R2 < 0.98 of regression indicates quality problems in the measurements (scattering, 
outliers, run-to-run variation). Laboratories 2, 9, 12, and 21 work with an instrument with 
higher scattering of the data. Therefore the threshold for these laboratories was reduced to 
0.97.  
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- During the data analysis, the results obtained when linear regressions were forced through 
0 (y = bx) were compared to those when linear regressions were performed with an intercept 
(y = a+bx). The mean of means of the TFs were very comparable, but the standard 
deviations were higher in the second case. However, as in the second case only measured 
data were used and no model other than the linearity within the actual measurement interval 
was assumed it was decided to process the data allowing for intercepts in the linear 
regression, provided that the intercept ± 4 SD covers the origin. As a consequence, the 
criterion for the acceptance of datasets was adapted, and a (within laboratory) day-to-day 
RSD of 5 % defined.  
- For A2M many methods have a lower precision, which results in higher day-to-day 
variations for these proteins. Therefore, in these cases day-to-day RSD of 8 % were 
accepted. 
- On the basis of criteria 3, 4, 5, and 6, datasets with general quality problems were 
excluded. 
6.4 Results of the value transfer measurements 
6.4.1 General considerations 
The characterisation measurements were performed by 18 laboratories. Of these 
laboratories 6 used an open value transfer procedure and 14 a closed value transfer 
procedure (Table 11). They are coded from laboratory 1 to 22, as some laboratories which 
first intended to participate dropped out. In the plots number 23 was used for laboratories 
having measured a second dataset for a particular protein, the reader can refer to Table 11 
to know which laboratories performed these measurements. Two of the laboratories normally 
measuring with the open protocol did additional measurements using the closed protocol. 
The planning of the measurements was governed by the aim to obtain at least twelve 
datasets per protein, with preferably at least one dataset for all major platform / reagent 
combinations in an open mode. The Beckman Immage can not be run in the open mode, for 
this platform only data with a closed value transfer procedure were obtained. The 
measurement of A2M is only supported by a limited number of platforms and laboratories, 
and only 6 datasets were retained for this protein. For the other proteins the characterisation 
is based on between 10 and 14 valid datasets each. 
The performance of the measurements was very demanding, particularly for laboratories 
measuring many proteins. As each platform has its particularities (time taken by the 
measurements, order of the measurements, intermediate storage of the samples in a closed 
environment or not, etc.) the planning of the order of the measurements had to be done 
separately by each laboratory.  
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The requirement that all the dilutions are prepared from a single vial made the volumes of 
the dilutions available small, and required the optimisation of the dilution scheme for the 
different platforms, depending on their sample intake. 
One of the possible problems was the evaporation of samples, which can become significant 
when small sample volumes are used (as was the case here), and when the samples are 
stored on the platform for a long time before they are measured (as is the case with slower 
platforms and when many proteins are measured). This problem was avoided in different 
ways, for example by measuring fewer proteins per series of dilutions, or capping the 
samples between measurements. The dilutions have been measured in different orders by 
different laboratories, and some laboratories have measured in different orders on different 
days. Overall no significant differences were detected between laboratories running the 
samples in different orders. Laboratory 2 kindly accepted to measure the dilutions one by 
one, instead of in one analytical series. There is no significant evaporation between dilutions 
in their measurements, and their results are mostly in line with those of other laboratories. 
Hence they confirm that there is no significant impact from evaporation on the measurement 
results.  
 
6.4.2 Scrutiny of the data 
The results are summarised in Tables 10 (summary of data problems) and 11 (results 
obtained). In Table 11 the grey cases correspond to laboratory / protein combinations for 
which measurements were reported. If, for these cases, no number is given there were no 
valid measurements for that combination (according to the acceptance criteria defined under 
Section 6.3, and the results from the analysis described below). In those cases the main 
reason for the invalidity of the results is indicated. 
 
The results obtained with closed and open characterisation procedures are very similar (Fig. 
3). The only protein for which the difference is significant according to a t-test at the 95 % 
confidence interval is A2M, but for A2M only 2 datasets were measured with the open 
instrument mode.  
As part of the scrutiny, all outlying values were identified, at the level of individual 
measurements and at the level of TFs. Outliers were not deleted automatically, but possible 
technical reasons for outlying values were examined with the laboratories involved. As a 
result the following decisions were taken: 
- A number of typographical errors were corrected. 
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- For laboratory 2, data from day 1 were not used, as the data for this day were incomplete, 
and some issues concerning sample evaporation were still being tested. As on days 2, 3, 
and 4 the dilutions were not measured in one analytical sequence, but separately, data 
giving a correlation coefficient of 0.96 were accepted (instead of 0.97). 
- For laboratory 8, data from measurement day 2 on group 1 proteins (AAT, HPT, IgA, IgG, 
and TRF) were not used. There had been a delay in the measurement of certain dilutions 
because of technical problems with the platform, and this had led to evaporation of these 
dilutions. 
- For laboratory 5 data on C4 were withdrawn because of technical reasons leading to 
reproducibility problems. 
- For laboratory 4, the data points for the highest concentration were not used for IgG and 
HPT, because they are at the limit of the measuring interval.  
Figure 3: Comparison of TFs obtained with open (light bars) and closed (dark bars) 
characterisation protocols. The height of the bars correspond to the average values per 
protein. The error bars represent ± SD. 
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Table10: Number of measurement days excluded and occurrence of different data problems. 
Note that the data of one measurement day may have different types of problems 
 Number of occurrences of: 
Number of 
measurement 
days Protein 
Analysed Non-valid 
Days not 
used 
> 50 % of 
the data is 
missing 
Non-
overlapping 
confidence 
intervals 
Correlation 
coefficient 
below limit 
< 2 valid 
days 
Day-to-
day 
variation 
above 
limit 
  A2M 32 6 1 1 1 1  4 
  AAG 63 17 1 2 2 5 1 12 
  AAT 51 7 2   6 1  
  ALB 52 6 1 1 1 3   
  C3c 51 1  1     
  C4 55 11 5   6  4 
  HPT 54 9 2  1 4  4 
  IgA 54 7 2 1 2 2   
  IgG 53 5 2 1 1 2   
  IgM 51 11 1  1 5 1 4 
  TRF 55 15 2  1 6  8 
  TTR 47 7 1  2   4 
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Table 11: Summary of the measurements performed by the participating laboratories1.  For each protein / laboratory combination the mean of the valid 
daily TFs is given 
Laboratory/ 
procedure 
used 
Platform A2M AAG AAT ALB C3c C4 HPT IgA IgG IgM TRF TTR 
L1/ closed BNII 0.8892 0.9228 0.9416 0.9243 0.9095 1.0768 0.9726 0.8994 0.9308 0.9294 DTD  
L2/ closed Immage CI DTD CC 0.9301 0.8936 1.0006 1.0136 0.9223 0.9404 DTD 0.9648 0.9103 
L3/ open AU640  0.9579 0.9437  0.9399 1.0836 0.9907 0.9341 0.9523 0.9286 0.9640 0.9202 
L4/ open BN II 0.8405 0.9016 0.8769 0.9100 0.9166 1.038 0.9668 0.8706 0.9205 0.8686 0.9716 0.9012 
L4/ closed BN ProSpec 0.8820            
L5/ open Hitachi 917 0.8602 0.9641 0.9394 0.9301 0.9271  0.9838 0.9215 0.9699 0.9125 0.9658 0.9121 
L7/ closed BN ProSpec  0.9408  0.9222        0.8988 
L8/ open Hitachi 917  0.9348 0.9420 0.9488 0.9367 1.0956 0.9788 0.9225 0.9486 0.9113 0.9704 0.9213 
L8/ closed Hitachi 917      1.1002       
L9/ closed Immage  CC, DTD 0.9516          
L10/ closed Integra  0.9434 0.9340    1.0104    0.9409  
L11/ closed BN ProSpec  DTD DTD 0.9303 0.9740 DTD 1.1248 DTD 0.8972 0.9508 CC CC DTD 
L12/ closed Immage 0.8796 DTD 0.8650 0.9797 0.8887 1.0534 1.0208 0.9208 0.9449 0.8853 DTD 0.8655 
L13/ open Architect   0.9437 0.9419 0.9373 0.9148 1.0601 0.9845 0.9115 0.9346 0.9007 0.9359 0.9117 
L13/ open Architect    0.9301         
L14/ closed LX-22002  0.9654   0.9430 DTD 1.0422 0.9684 0.9584 0.9303 0.9899  
L17/ closed Hitachi 917     0.9253 1.0844  0.9134 0.9595 0.9033 0.9666  
L18/ closed Hitachi 717  0.9258   0.9204 1.0735 0.9701 0.9203 0.9437 0.8993 0.9594  
L19/ closed Hitachi 919  0.9408 0.9516 0.9231        0.9227 
L21/ closed Immage 0.8752   0.9444   1.0080 0.9296 0.9581   0.8941 
L22/ open Hitachi 917  0.9473 0.9336 0.9167 0.9213 1.0533 0.9964 0.9244 0.9546 0.9140 0.9804 0.9078 
1cases are coloured grey for those laboratory / protein combinations for which data has been analysed. In case the data was valid the mean of the valid daily 
determinations is given. In case the data for that laboratory/protein combination was not valid the main reason is indicated by one of the following abbreviations: CI 
non-overlapping confidence intervals; DTD: the day-to-day variation exceeds the acceptance limit; CC: the correlation coefficient exceeds the acceptance limit.
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6.4.3 Results per protein 
 
A2M 
Only 8 laboratories could measure A2M, and only 2 of those measured it with the open 
instrument protocol. The 6 valid datasets provided acceptable results, but the uncertainty of 
the characterisation is higher than for most other proteins (see Table 12) because of the 
scattering of the values and the limited number of datasets (Fig. 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Results of the characterisation measurements for A2M The bars represent the 
laboratory means ± SD. The dotted line represents the mean of means, and the bars at the beginning 
and the end of the dotted line represents the mean of means ± SD. 
 
AAG 
For AAG the assigned value is the mean of means of 12 datasets. None of these was 
flagged as an outlier (Fig. 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Results of the characterisation measurements for AAG The bars represent the 
laboratory means ± SD. The dotted line represents the mean of means, and the bars at the beginning 
and the end of the dotted line represents the mean of means ± SD. 
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AAT 
For the measurement of AAT the mean value of laboratory 12 is an outlier (Fig. 6) at the 
95 % confidence level according to Grubbs test results. Two other laboratories were using 
the same platform/reagent combination, and there is thus also no reason to suspect that the 
differing results are method dependent. The uncertainty of the value of Laboratory 12, as 
calculated from the day-to-day variation, is such that the 95 % confidence interval of the 
value covers the mean of means of all the laboratories. Therefore the value from Laboratory 
12 was retained for the calculation of the mean of means. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Results of the characterisation measurements for AAT The bars represent the 
laboratory means ± SD. The dotted line represents the mean of means, and the bars at the beginning 
and the end of the dotted line represents the mean of means ± SD. 
 
ALB 
The mean TFs of Laboratory 11 and 12 are outliers (Fig. 7) at the 95 % confidence level 
according to Grubbs test results, but they do not represent a single method. They are also 
within the 95 % tolerance interval, and values were accepted.. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 7: Results of 
the characterisation measurements for ALB The bars represent the laboratory means ± SD. The 
dotted line represents the mean of means, and the bars at the beginning and the end of the dotted 
line represents the mean of means ± SD. 
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C3c 
The value for C3c is the mean of means of 12 valid datasets (Fig. 8). Many laboratories 
show a very low day-today variation for this protein, but the scatter of the laboratory means 
is not reduced. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: 
Results of the characterisation measurements for C3c The bars represent the laboratory means ± 
SD. The dotted line represents the mean of means, and the bars at the beginning and the end of the 
dotted line represents the mean of means ± SD. 
 
 
C4 
The value for C4 is the mean of means of 12 valid datasets (fig. 9). None of these were 
flagged as outliers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Results of the characterisation measurements for C4 The bars represent the laboratory 
means ± SD. The dotted line represents the mean of means, and the bars at the beginning and the 
end of the dotted line represents the mean of means ± SD. 
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HPT 
The value for HPT is the mean of means of the results of 13 laboratories (Fig. 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Results of the characterisation measurements for HPT The bars represent the 
laboratory means ± SD. The dotted line represents the mean of means, and the bars at the beginning 
and the end of the dotted line represents the mean of means ± SD. 
 
 
IgA 
There are data from 14 laboratories for IgA, and most of them cluster quite closely (Fig. 11). 
The mean TF of Laboratory 14 is an outlier at a 95 % confidence level according to Grubbs 
test results, and it is also a unique platform. However, as the day-to-day variation of 
Laboratory 14 is also high the 95 % confidence interval of this laboratory covers the mean of 
means, and Laboratory 14 was included for the calculation of the certified value. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 
11: Results of the characterisation measurements for IgA The bars represent the laboratory 
means ± SD. The dotted line represents the mean of means, and the bars at the beginning and the 
end of the dotted line represents the mean of means ± SD. 
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IgG 
The value assigned for IgG is the mean of means of the results of 14 laboratories (Fig. 12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Results of the characterisation measurements for IgG The bars represent the 
laboratory means ± SD. The dotted line represents the mean of means, and the bars at the beginning 
and the end of the dotted line represents the mean of means ± SD. 
 
 
IgM 
The value assigned for IgM is the mean of means of the results of 11 laboratories (Fig. 13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Results of the characterisation measurements for IgG The bars represent the 
laboratory means ± SD. The dotted line represents the mean of means, and the bars at the beginning 
and the end of the dotted line represents the mean of means ± SD. 
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TRF 
The value assigned for TRF is the mean of means of the results of 11 laboratories (Fig. 14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 
14: Results of the characterisation measurements for TRF The bars represent the laboratory 
means ± SD. The dotted line represents the mean of means, and the bars at the beginning and the 
end of the dotted line represents the mean of means ± SD. 
 
 
TTR 
The mean TF of Laboratory 12 is an outlier (Fig. 15) at the 95 % confidence level according 
to Grubbs test results, but as it does not represent a unique method, is within the 99 % 
confidence interval and within the 95 % tolerance interval the data of laboratory 12 were 
retained. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Results of the characterisation measurements for TTR The bars represent the 
laboratory means ± SD. The dotted line represents the mean of means, and the bars at the beginning 
and the end of the dotted line represents the mean of means ± SD. 
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6.5 Summary of the results of the characterisation study 
 
The results of the characterisation study are the transfer factors TF = CT/CR, determined for 
each protein. They are calculated as the mean of the means of the results per laboratory, 
using only the valid datasets. The relative standard uncertainty related to the 
characterisation uchar is taken as the relative standard error of the mean of the means of the 
valid datasets. 
 
Table 12: Mean of means and uncertainty of the TFs, calculated using all valid results 
TF 
Protein 
Mean of means RSD [%] 
uchar [%] 
       A2M 0.8711 2.047 0.836 
       AAG 0.9407 1.928 0.557 
       AAT 0.9293 3.026 0.874 
       ALB 0.9346 2.230 0.619 
       C3c 0.9197 1.828 0.528 
       C4 1.0704 3.022 0.873 
       HPT 0.9953 2.262 0.627 
       IgA 0.9183 2.364 0.632 
       IgG 0.9477 1.375 0.368 
       IgM 0.9076 2.109 0.636 
       TRF 0.9645 1.603 0.483 
       TTR 0.9060 1.801 0.543 
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7 Uncertainty budgets and certified values  
7.1 Estimation of the uncertainties 
The certified uncertainties consist of relative standard uncertainties related to 
characterisation (uchar), the relative standard uncertainties of the calibrant (ucal), between-
bottle heterogeneity (ubb), and degradation during long-term storage (ults) [13]. 
• uchar was estimated as the relative standard error of the mean of laboratory means, i.e. 
SD/(p)0.5 with RSD the relative standard deviation of the mean of means and p the 
number of datasets.  
• ucal was estimated as half the half-width of the 95 % confidence interval of the certified 
value of the protein in the calibrant, ERM-DA470, relative to the certified value. 
• ubb was estimated as the relative standard deviation between-units (sbb) or the maximum 
heterogeneity potentially hidden by method repeatability (u*bb) as defined in Section 4.1 
(Table 5). The higher of these two values was taken as a conservative estimate of 
potential heterogeneity.  
• ults was estimated from stability tests and were taken from Table 8 (12 months stability 
study). 
The relative combined standard uncertainty were calculated as the square root of the sum of 
squares of the individual contributions, according to: 
2
lts
2
bb
2
cal
2
charc uuuuu +++=   
The various uncertainty contributions and the relative combined standard uncertainty (uc) are 
shown in Table 13. 
 
Table 13: Uncertainty budget for ERM-DA470k/IFCC 
Protein uchar [%] 
ucal 
[%] 
ubb 
[%] 
ults 
[%] 
uc 
[%] 
A2M 0.836 1.53 0.517 0.669 1.93 
AAG 0.557 0.382 0.484 0.632 1.04 
AAT 0.874 0.456 0.675 0.410 1.26 
ALB 0.619 1.01 0.612 0.567 1.45 
C3c 0.528 1.24 0.557 0.445 1.52 
C4 0.873 1.66 0.418 0.497 1.98 
HPT 0.627 0.504 0.637 0.494 1.14 
IgA 0.632 1.02 0.340 0.357 1.30 
IgG 0.368 0.516 0.425 0.615 0.98 
IgM 0.636 1.44 0.745 0.562 1.83 
TRF 0.483 1.22 0.498 0.646 1.55 
TTR 0.543 3.71 0.880 0.592 3.89 
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7.2 Certified values 
For each protein the certified value (Table 14) was calculated from the TF (Table 12) and the 
certified value of the proteins in ERM-DA470 (Table 9) according to: 
DA470ERMDA470kERM TF −− ⋅= cc  
Relative expanded uncertainties were calculated from the relative combined standard 
uncertainty uC (Table 13) by multiplication with a coverage factor k. This coverage factor was 
taken as 2. Relative expanded uncertainties were multiplied with the mean of retained 
dataset means to obtain absolute expanded uncertainties UCRM.  
 
Table14: Certified values and expanded uncertainties for mass fractions of proteins in ERM-
DA470k/IFCC 
Protein Certified value [g/L] 
UCRM (k = 2) [g/L] 
       A2M 1.43 0.06 
       AAG 0.617 0.013 
       AAT 1.12 0.03 
       ALB 37.2 1.2 
       C3c 1.00 0.04 
       C4 0.162 0.007 
       HPT 0.889 0.021 
       IgA 1.80 0.05 
       IgG 9.17 0.18 
       IgM 0.723 0.027 
       TRF 2.36 0.08 
       TTR 0.220 0.018 
 
 
 
 
 
49 
8 Metrological traceability 
 
The measurements of A2M, AAG, AAT, ALB, C3c, C4, HPT, IgA, IgG, IgM, TRF, and TTR 
were calibrated with ERM-DA470 applying the value transfer procedure as described in the 
report. The value transfer measurements were strictly controlled with respect to the 
adherence to the procedure and the adequate functioning of equipment and reagents 
verified. The methods used were either immunochemical or visual spectrometry (only for 
ALB). Different combinations of reagents and platforms were used, and gave consistent 
results. Therefore the results are not dependent on the individual methods. 
The value assignment measurements of A2M, ALB, C3c, C4, HPT, IgA, IgG, and IgM in 
ERM-DA470 had been calibrated with USNRP 12-0575C, also using immunochemical 
methods and a similar value transfer procedure [2]. The values of the proteins in the 
calibrant USNRP 12-0575C had been assigned on the basis of measurements by 24 
laboratories using different in-house calibrants of unspecified origin and purity [3]. Therefore 
the traceability chain can not be extended further than to the USNRP 12-0575C, and the 
certified mass concentrations, of A2M, ALB, C3c, C4, HPT, IgA, IgG, and IgM in ERM-
DA470k/IFCC are traceable to the stated values of the mass concentrations in the USNRP 
12-0575C, applying the procedures described for the certification of ERM-DA470 and in the 
present report.  
The certified values for AAG, AAT, TRF, and TTR in ERM-DA470 were obtained by 
calibration with pure proteins [14]. Consequently, the certified mass concentrations, for AAG, 
AAT, TRF and TTR in ERM-DA470k/IFCC are traceable to the International System of Units 
(SI), applying the procedures described in the certification report of ERM-DA470 [2] and in 
the present report. 
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9 Commutability 
 
During the value assignment procedure it was found that there were no significant matrix 
effects. This was done by verifying that the regression line of the signal measured for the 
protein concentrations in the dilutions in function of the volume fraction of the certified 
reference material in the dilutions was linear, and passed through the origin. Also, the 
following methods (combinations of platforms and reagents) produced consistent results: 
 
- Abbot Architect, Abbott reagents 
- Beckman Immage, Beckman reagents 
- BN II, Dade Behring reagents 
- BN ProSpec, Dade Behring reagents 
- Hitachi 717, MBL reagents 
- Hitachi 917, DAKO reagents 
- Hitachi 917, Denka Seiken reagents 
- Hitachi 917, Roche reagents 
- Hitachi 919, Nitto Boseki reagents 
- LX-2200, Eiken reagents 
- Roche Integra, Roche reagents 
 
The equivalence of the material with patient samples has to be demonstrated for each 
particular assay. However, the results of external quality assurance schemes show that the 
inter-assay variation of the proteins certified has generally been significantly reduced during 
the long-term use of ERM-DA470 [4, 5]. As this is a strong indication of commutability ERM-
DA470k/IFCC was produced in a similar manner, and it can be expected to be equally 
commutable. 
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10 Intended use and instructions for use 
The material is primarily intended to be used for the calibration of immunoassay-based in-
vitro diagnostic devices or control products for the proteins certified.  
When the material is used as a calibrant in a particular assay the commutability should be 
verified for the assay concerned.  
The entire content of the vial must be reconstituted. 
 
Reconstitution of the material 
To make it ready for use, the material has to be reconstituted according to the following 
procedure: 
• Remove the vial from the freezer or refrigerator during the afternoon of the day before 
use and place the vial for 1 hour in the room where the balance is located. 
• After 1 hour, tap the bottom of the vial gently on the surface of the table. Make sure that 
all the material has settled down on the bottom of the vial. Remove the screw cap. 
• Weigh the vial together with the rubber stopper. Note down the mass or press the 
“TARE” knob on the balance. Lift the rubber stopper with care until air is allowed to enter 
the vial and the groove in the rubber stopper becomes accessible. 
• Add 1.00 mL  of water through the groove, and press the rubber stopper back into place. 
Weigh the vial and note down the mass. If you have used the “TARE” function, the value 
can be used directly for the mass m. Otherwise the first mass must be subtracted from 
the second to obtain m. 
• The concentration of a particular protein in the solution, corrected for the reconstitution 
mass, can be obtained by multiplying the certified value for that protein with mintended / m, 
with mintended the mass intended to be added (1.000 g).  
• Leave the vial at room temperature for one hour, then invert it carefully at least five times 
(do not shake it) during the next hour. 
• Leave the vial at room temperature overnight. On the day of use invert the vial carefully 
five times during one hour. 
 
Storage 
Unopened ampoules should be stored at – (20 ± 2) °C. Under the condition that any 
microbial contamination during the reconstitution procedure has been excluded, the solution 
of ERM-DA470k/IFCC can be used for one week, as it was verified that changes to the 
certified concentration observed during that period are not significant. It is advisable to cover 
the vial with the original seal after use and to store it at 2 to 8 °C. However, the European 
Commission cannot be held responsible for changes that happen during storage of the 
material at the customer's premises, especially of opened samples. 
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Abstract 
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ERM-DA470, is described.  
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was achieved using a value transfer protocol that can be considered as reference procedure.  
The techniques used to measure the protein concentrations were immunonephelometry, immunoturbidimetry, and for 
ALB also visible spectrometry. The measurements were performed with different platform/reagent combinations 
(Abbott Architect, Beckman Immage, BN II and BN ProSpec, different Hitachi instruments, Roche Integra, LX 2200, 
and Olympus AU640). In total 18 laboratories participated in the value assignment, 4 using open value transfer 
procedures, 12 using closed value transfer procedures, and 2 using both open and closed procedures. 
The results show that open and closed value transfer procedures give very similar results, and lead to robust values 
for A2M, AAG, AAT, ALB, C3c, C4, HPT, IgA, IgG, IgM, TRF, and TTR.  
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